公开(公告)号：US11844793B2

公开(公告)日：2023-12-19

申请号：US17449412

申请日：2021-09-29

Applicant: AeroRx Therapeutics LLC

Inventor： John Chan ,  Keith Try Ung ,  Mei-Chang Kuo ,  John Nigel Pritchard

IPC: A61K31/4704 ,  A61K31/5386 ,  A61K31/40 ,  A61K9/00 ,  A61K47/69 ,  A61K47/26 ,  A61K31/58 ,  A61K9/08 ,  A61K9/12 ,  A61K47/10 ,  A61P11/00

CPC classification number: A61K31/4704 ,  A61K9/0078 ,  A61K9/08 ,  A61K9/12 ,  A61K31/40 ,  A61K31/5386 ,  A61K31/58 ,  A61K47/10 ,  A61K47/26 ,  A61K47/6951 ,  A61P11/00

Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

公开(公告)号：US20230398131A1

公开(公告)日：2023-12-14

申请号：US18154695

申请日：2023-01-13

Applicant: LEO Pharma A/S

Inventor： Marianne LIND ,  Gritt RASMUSSEN ,  Mette Rydahl SONNE ,  Jens HANSEN ,  Karsten PETERSSON

IPC: A61K31/593 ,  A61K31/59 ,  A61K47/06 ,  A61K47/08 ,  A61M11/00 ,  A61K9/00 ,  A61K9/12 ,  A61K31/573 ,  A61K31/58 ,  A61M35/00 ,  A61K47/14 ,  A61K47/22

CPC classification number: A61K31/593 ,  A61K31/59 ,  A61K47/06 ,  A61K47/08 ,  A61M11/00 ,  A61K9/0014 ,  A61K9/122 ,  A61K31/573 ,  A61K31/58 ,  A61K9/124 ,  A61M35/003 ,  A61K47/14 ,  A61K47/22 ,  A61M2210/04 ,  B65D83/207

Abstract: The present invention relates to a topical spray composition comprising a biologically active vitamin D derivative or analogue and a corticosteroid, and its use in the treatment of dermal diseases and conditions.

公开(公告)号：US11813288B1

公开(公告)日：2023-11-14

申请号：US18219009

申请日：2023-07-06

Applicant: KING FAISAL UNIVERSITY

Inventor： Hany Mohamed Abd El-Lateef Ahmed ,  Saadeldin Elsayed Ibrahim Shabaan ,  Jihad Wadai Saleh Alessa

IPC: A61K33/26 ,  A61K31/245 ,  A61K36/14 ,  A61K9/12 ,  A61K36/54 ,  A61K47/46

CPC classification number: A61K33/26 ,  A61K9/12 ,  A61K31/245 ,  A61K36/14 ,  A61K36/54 ,  A61K47/46

Abstract: Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe3O4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe3O4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 μm). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 μm-100 μm to ensure effective binding to virions.

公开(公告)号：US20230355485A1

公开(公告)日：2023-11-09

申请号：US18124291

申请日：2023-03-21

Applicant: FORMULATED SOLUTIONS, LLC

Inventor： Stephen BALDWIN ,  Scott CARPENTER ,  Heidi GRAHAM ,  Nanhye KIM ,  Tom MEYER ,  David Reynolds ,  Jerry Vancleave ,  Eric DANN ,  Thomas DANN ,  Renee NELSON ,  Brian DANN

IPC: A61Q17/04 ,  A61Q11/00 ,  A23P30/40 ,  B65D83/62 ,  A61K8/27 ,  A61Q5/06 ,  B65D83/20 ,  A61K8/19 ,  A61K8/04 ,  A61Q19/00 ,  A61Q7/00 ,  B65D83/14 ,  A61K9/12

CPC classification number: A61K8/046 ,  A23P30/40 ,  A61K8/19 ,  A61K8/27 ,  A61K9/122 ,  A61Q5/06 ,  A61Q7/00 ,  A61Q11/00 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/004 ,  B65D83/207 ,  B65D83/62 ,  B65D83/752 ,  A61K2800/22 ,  A61K2800/87

Abstract: The present disclosure relates to, inter alia, a formulation in a package. The formulation comprises one or more active agents and is co-mingled with a whipping agent prior to being filled under pressure into the package. The whipping agent is added in sufficient amounts to be dispersed in the formulation. The pressurized package is under sufficient pressure suitable to maintain the whipping agent dispersed in the formulation; and the pressurized package is under sufficient pressure to expel the formulation as a whipped formulation upon application of external force on the formulation in the package.

公开(公告)号：US11793820B2

公开(公告)日：2023-10-24

申请号：US17952238

申请日：2022-09-24

Applicant: Chadwick Donaldson ,  Adam Haeberle ,  Joseph Fuisz

Inventor： Chadwick Donaldson ,  Adam Haeberle ,  Joseph Fuisz

IPC: A61K31/66 ,  A61K9/12 ,  A61K9/14 ,  A61K31/56 ,  A61K9/00 ,  A61P1/04 ,  A61K45/06 ,  A61K31/58

CPC classification number: A61K31/66 ,  A61K9/006 ,  A61K9/0031 ,  A61K9/122 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  A61P1/04

Abstract: Embodiments include formulations and methods for oromucosal administration of a dry powder to create a topical foam composition to deliver medicaments to an interior mucosal space, such as the oral cavity, nasal cavity, rectal cavity, vaginal cavity or esophagus. The active agent can be amifostine, an antibiotic, an anti-fungal, a non-steroidal anti-inflammatory drug or a steroidal anti-inflammatory drug. Oromucosal delivery allows one to target oral epithelial cells. Embodiments also include methods of treating mucositis. Conventional formulations and methods are generally ineffective because drugs cannot be directed toward epithelial cells of the GI that are most susceptible to mucositis. The formulations described herein increase concentration, permeability and residence time at a target site. The formulations also allow stable forms of amifostine, which obviates difficulties associated with storing, dosing and administering the drug.

公开(公告)号：US11779560B2

公开(公告)日：2023-10-10

申请号：US17211778

申请日：2021-03-24

Applicant: COEURATIVE, INC.

Inventor： John Frederick Schmedtje, Jr.

IPC: A61K31/34 ,  A61K9/00 ,  A61K9/12 ,  A61K9/20 ,  A61K9/48 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/20

CPC classification number: A61K31/34 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/12 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/186 ,  A61K47/20

Abstract: The present invention provides novel methods of using nitric oxide donor compounds for treating infectious diseases, for example, COVID-19.

公开(公告)号：US11779446B2

公开(公告)日：2023-10-10

申请号：US16196872

申请日：2018-11-20

Applicant: 3M INNOVATIVE PROPERTIES COMPANY

Inventor： Katie F. Wlaschin ,  Amanda C. Engler ,  Hannah C. Cohen ,  Yizhong Wang ,  Tao Gong ,  Tiffany T. Ton ,  Joel D. Oxman ,  Jie Yang ,  Richard P. Rusin

IPC: A61C19/06 ,  A61P1/02 ,  A61K36/00 ,  A61Q11/00 ,  A61K9/12 ,  A61K8/25 ,  A61K8/41 ,  A61K8/73 ,  A61K8/92 ,  A61K47/12 ,  A61K9/107 ,  A61K47/26 ,  A61K8/81 ,  A61K8/06 ,  A61K9/00 ,  A61K47/10 ,  A61K8/37 ,  A61K36/185 ,  A61K47/36 ,  A61K47/44 ,  A61K36/28 ,  A61K36/63 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/48 ,  A61K36/52 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81

CPC classification number: A61C19/063 ,  A61K8/062 ,  A61K8/25 ,  A61K8/375 ,  A61K8/41 ,  A61K8/73 ,  A61K8/731 ,  A61K8/732 ,  A61K8/737 ,  A61K8/8147 ,  A61K8/8176 ,  A61K8/922 ,  A61K9/006 ,  A61K9/0053 ,  A61K9/107 ,  A61K9/12 ,  A61K31/025 ,  A61K31/075 ,  A61K31/164 ,  A61K31/198 ,  A61K31/205 ,  A61K31/355 ,  A61K31/714 ,  A61K31/728 ,  A61K36/00 ,  A61K36/185 ,  A61K36/28 ,  A61K36/48 ,  A61K36/52 ,  A61K36/63 ,  A61K36/736 ,  A61K36/752 ,  A61K36/81 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/44 ,  A61P1/02 ,  A61Q11/00

Abstract: Compositions that include: from 5 wt-% to 30 wt-% of one or more plant based oils based on the total weight of the composition; from 70 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; from 0.1 wt-% to 5 wt-% of one or more surfactants based on the total weight of the composition; and from 0.05 wt-% to 3 wt-% of a viscosity modifier, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.

公开(公告)号：US20230255944A1

公开(公告)日：2023-08-17

申请号：US17965859

申请日：2022-10-14

Applicant: AI Therapeutics, Inc.

Inventor： Thomas Armer ,  Lawrence S. Melvin, JR. ,  Jonathan M. Rothberg ,  Henri Lichenstein

IPC: A61K31/436 ,  A61K45/06 ,  A61K9/00 ,  A61K9/12 ,  A61K31/557 ,  A61K9/16

CPC classification number: A61K31/436 ,  A61K45/06 ,  A61K9/0075 ,  A61K9/12 ,  A61K31/557 ,  A61K9/1617 ,  A61K9/1623

Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.

公开(公告)号：US20230226121A1

公开(公告)日：2023-07-20

申请号：US17725587

申请日：2022-04-21

Applicant: Mark Edward Fenzl

Inventor： Mark Edward Fenzl

IPC: A61K35/644 ,  A61K9/00 ,  A61K9/12 ,  A61K36/18 ,  A61K36/899 ,  A61K31/167 ,  A61K36/79 ,  A61K36/61 ,  A61K33/40 ,  A61K33/00

CPC classification number: A61K35/644 ,  A61K9/0014 ,  A61K9/122 ,  A61K36/18 ,  A61K36/899 ,  A61K31/167 ,  A61K36/79 ,  A61K36/61 ,  A61K33/40 ,  A61K33/00

Abstract: The present invention relates to an improved wound product that is equivocal to manuka honey in antimicrobial and wound healing effectiveness, but may be mixed with a therapeutic anesthetic, may have a fragrance, may be stored in a spray dispenser, may be used with a straw, and is applied as a foam. This provides the option of a straw being attached to the dispenser hole for dispensing honey foam for deep tunneling wound. It may also be sprayed directly on the wound or burn, or be sprayed on a sterile sponge for application.

公开(公告)号：US20230183293A1

公开(公告)日：2023-06-15

申请号：US17923552

申请日：2021-05-08

Applicant: Aurinia Pharmaceuticals Inc.

Inventor： Y.K. Onno TENG ,  Robert B. HUIZINGA ,  Neil SOLOMONS ,  Jennifer CROSS

IPC: C07K7/64 ,  A61K31/5377 ,  A61K31/573 ,  A61K9/12 ,  A61P31/14

CPC classification number: C07K7/64 ,  A61K31/5377 ,  A61K31/573 ,  A61K9/12 ,  A61P31/14

Abstract: Provided herein are methods of using voclosporin for treating or preventing coronavirus infection, particularly in subjects that require immunosuppression.